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Abstract:
Background:
Mycosis Fungoides (MF) is the most frequent type of the primary cutaneous NK/T-cell lymphomas. Ingenol mebutate (IM) displays
in vitro pro-apoptotic properties on neoplastic lymphocytes.
Objectives:
To evaluate the efficacy and safety of IM gel as topical treatment for MF.
Materials and Methods:
Ten  male  patients  with  longstanding  classic  type  MF (n=9)  and  follicular  MF (FMF;  n=1),  T2bN0M0B0,  stage  Ib,  resistant  to
systemic methotrexate  or  acitretin  therapies  for  at  least  3  months,  were  included in  this  pilot  study.  In  these  patients,  11 target
patch/plaque stage lesions with an area ≤ 25 cm2 were selected for IM therapy (0,05%, 2 weekly applications). The primary endpoint
was the improvement of the CAILS scores. Biopsies were performed before and after treatment from 10 target lesions. Relapse rates
were evaluated at 6 months.
Results:
The mean CAILS score of treated target lesions was reduced by 58.2%. The mean erythema, scaling and plaque elevation scores
were  improved  by  73.6%,  93.9%  and  97.9%  (p<0.0001),  respectively,  while  the  lesion  size  remained  unchanged  (p=0.34).  A
complete or partial clearance of histological and immunohistochemical features was observed in 6/10 (60%) and 4/10 (40%) of the
MF or FMF target lesions, respectively. Monoclonal TCR rearrangement was evidenced in 100% (7/7) of the patients and in 3/7
(43%) after treatment. The relapse rate at 6 months was 18%. All the patients experienced burning sensations, oozing and crusting.
Conclusion:
IM gel warrants further investigation and development as a potential topical treatment for localized patch/plaque stage MF and FMF.
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1. INTRODUCTION
Ingenol Mebutate (IM) is a macrocyclic diterpene ester and originates from the plant Euphorbia peplus (PEP005,
0,015%,  0,05%,  Picato°  gel,  Leo  Pharma)  [1,  2].  For  decades  the  sap  from E.  peplus  has  been  used  as  traditional
medicine  for  various  types  of  skin  cancer  [1,  2].  Both the  EMA and the  FDA recognize  IM gel  as  a  field-directed
treatment for Actinic Keratosis (AK) [1, 2]. IM also revealed to be an efficacious topical treatment for other cutaneous
(Fig.  3)  epithelial  cancers,  including  superficial  basal  cell  carcinoma  [3  -  5],  Bowen’s  disease  [6,  7]  and  murine
cutaneous squamous cell carcinoma [8]. IM has also demonstrated activity against melanoma cell lines in vitro [9, 10]
and, in vivo, for Dubreuilh’s melanoma of the face [11].
IM and other ingenol derivatives activate multiple signaling pathways in cancer cells, including the intracellular
pro-apoptotic Protein Kinase C (PKC) δ, α and ϵ, NF-κB1, ERK, JNK and Akt pathways [10, 12]. The activation of
these PKC’s leads to a rapid cancer cell apoptosis and a neutrophil-mediated immunostimulation of antibody-dependent
cellular cytotoxic response [13]. The IM-induced pro-inflammatory and pro-apoptotic storm could potentially be of
therapeutic  benefit  for  atypical  lymphocytes.  Ingenol  3-angelate  has  previously  been  demonstrated  to  be  effective
against murine B-lymphoma cells [12]. IM induced apoptosis in acute myeloid leukemia cells by activating the PKC
isoform PKCδ [14].
The  classic  type  of  Mycosis  Fungoides  (MF)  is  the  most  frequent  form  of  the  primary  Cutaneous  T/NK  Cell
Lymphomas (pCTNKCL). MF follows typically an indolent cutaneous disease course and is an ideal candidate for skin-
directed therapies. Its folliculotropic variant (FMF) is a more rare and late-stage FMF may present a more aggressive
disease course [15 - 18].
In the view of the action mechanisms of IM, we were interested to evaluate whether IM gel 0,05% had a potential
effect on patch/plaque stage lesions in MF and FMF patients that were previously resistant to systemic methotrexate or
acitretin.
This  prospective  pilot  study  assessed  the  improvement  of  the  CAILS  (Composite  Assessment  of  Index  Lesion
Severity) score [19] and the histological cure rate 2 months after using IM gel on 11 target lesions in 10 patients with
histologically confirmed, longstanding patch/plaque stage MF and FMF.
2. MATERIALS AND METHODS:
2.1. Institutional Ethics
This  prospective  pilot  study  was  performed  in  accordance  with  the  ethical  standard  of  the  University  Hospital
Committee on institutional human experimentation and with the Helsinki Declaration of 1975, and amended in 2013.
The aims of the study and all the procedures were explained to all the patients and all signed an informed consent.
2.2. Patient Selection
At baseline, the patients had to present patch/plaque stage lesions that were not responding to at least 3 months of
oral methotrexate or acitretin treatments. Patients were selected between Feb and May 2017. The individual patient
demographics, including age, gender, type of underlying MF, TNMB staging and disease stage, mSWAT (modified
Severity-Weighted Assessment Tool) score of the underlying MF at baseline, as well as the site of the selected target
lesion are summarized in Table 1. All the patients had longstanding patch/plaque type classic type MF (n=9) or FMF
(n=1). The diagnosis of classic type MF or FMF was made histologically at least 4 years before inclusion in the study
and sustained by an immunohistochemical CD3+, CD4+, CD45R0+ and CD8- expression profile of the MF infiltrate
and by the presence of a monoclonal T-Cell Receptor (TCR) rearrangement (10/10 cases).
Table 1. Patient Demographics.
Patient Gender, Age Type, TNMB, Stage, mSWAT Target Lesion Site(s) Duration of MF (years)
1 M, 64 years FMF, T2bN0M0B0, Ib, 30 Perineal > 7
2 M, 52 years MF, classic type T2bN0M0B0, Ib, 82 Left arm > 5
3 M, 70 years MF, classic type T2bN0M0B0, Ib, 56 Left arm > 8
4 M, 62 years MF, classic type T2bN0M0B0, Ib, 84 Right arm > 5
5 M, 73 years MF, classic type T2bN0M0B0, Ib, 74 Chest > 4
6 M, 76 years MF, classic type T2bN0M0B0, Ib, 88 Knee > 5
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Patient Gender, Age Type, TNMB, Stage, mSWAT Target Lesion Site(s) Duration of MF (years)
7 M, 79 years MF, classic type T2bN0M0B0, Ib, 48 Knee > 8
8 M, 80 years MF, classic type T2bN0M0B0, Ib, 42 Axillar > 4
9 M, 65 years MF, classic type T2bN0M0B0, Ib, 78 Buttock > 5





Mean mSWAT score: 59.6 Mean duration of MF:
5.7 years
2.3. Target Site Selection
Per patient, one or two target patch/plaque type lesion(s) of 3 to 7 cm in diameter were selected. Target lesions had
to be present without any clinical changes since at least 3 months. Target lesions exceeding 25 cm2 were excluded, as
manufacturer instructions say to treat an area of not more than 25 cm2.
2.4. Control Site Selection
One or more control lesions in the immediate vicinity of the target lesion were selected. The size of the control
lesions was up to 25 cm2. The control lesions had to present a clinical highly similar aspect as the target lesion.
2.5. Photographic Recording
Photographic recordings were made of every target lesion and control lesion(s) under standard conditions at baseline
(T0) and at 2 months after therapy (T2).
2.6. Treatment Application
One tube of IM gel (0,05%, 235 µg of IM in 0,47 g of gel, Leo Pharma°) was applied to the target lesion at day 1
and day 7. The 0,05% formulation was selected, as none of the target lesions was located on the face. Patients were
informed  concerning  potential  adverse  effects  and  how  to  manage  them.  The  one-week  interval  between  IM
applications was selected to avoid too severe cutaneous adverse reactions as sometimes observed in AK patients with
the  2  consecutive  days  IM application  regimen,  and  furthermore,  to  be  able  to  judge  the  severity  of  the  cutaneous
reactions after one single application and to reduce the severity the IM-treatment-related adverse effects. The control
lesions did not receive any topical treatment. No other topical treatments were allowed for the target and control lesions
during the entire study. The previous oral treatments were interrupted three months before inclusion.
2.7. Histology, Immunohistology and TCR
A 4-mm cutaneous  punch  biopsy  of  the  target  lesion  was  obtained  under  local  anesthesia,  fixed  in  neutralized
formalin 4% and embedded in paraffin before and 2 months after treatment. Histopathological examination for MF
criteria was performed. The histologic scoring system was the following: no change compared to baseline, a partial
improvement (at least 75%) of the MF infiltrate or a total resolution (with or without persistence of post-inflammatory
lymphohistiocytic infiltrate and/or post-inflammatory hyperpigmentation). Immunohistochemistry searched for CD3,
CD4, CD45R0 and CD8 expressions. Immunohistological scoring was as follows: no change compared to baseline,
partial resolution (at least 75% improvement) and total healing in terms of CD3, CD4, CD45R0 and CD8 expression.
TCR monoclonal rearrangements were evaluated as present or absent at baseline and 2 months after treatment from 7
target lesions. No histology was performed for the control lesions.
2.8. CAILS Score
The primary endpoint in this pilot setting was the mean CAILS (Composite Assessment of Index Lesion Severity)
score  improvement,  expressed  in  percentage  (T0-T2),  evaluating  the  erythema,  scaling,  plaque  elevation  and
hyper/hypopigmentation scores (all: ranging from 0 (none) to 8 (very severe)) as well as the lesion size (1: up to 4 cm2
up to maximum 4: 16-25 cm2), as used for individual lesion evaluation, before (T0) and 2 months (T2) after treatment of
the target and control lesions [19].
2.9. Local Adverse Effects
Cutaneous local adverse effects assessment was performed 5 days after the first and second IM application. The
scoring  of  burning  sensations,  oozing,  and  crusting  used  the  following  scale:  0:  none,  1:  mild,  2:  moderate  and  3:
(Table 1) contd.....
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severe.  No evaluation of eventual systemic adverse effects was included in this pilot study as no such effects were
previously reported in AK studies [1 - 5].
2.10. Recurrence Rate
The clinical relapse rate of the target lesion was assessed 6 months after the initiation of the IM treatment. Relapse
was defined as the re-appearance of the patch/plaque infiltration and/or erythema and/or scaling.
2.11. Statistical Analysis
A comparison of the mean relative differences (T0 and T2) between target and control was made using the Student
test for the individual CAILS parameters, erythema, scaling, plaque elevation, hyper/hypopigmentation and lesion size
(L. Seidel).
3. RESULTS
3.1. Histology, Immunohistology and TCR
Punch biopsies were obtained from 10 target lesions before IM treatment (T0) and at 2 months after treatment (T2).
Histopathological examination revealed a complete or partial absence of histological signs and immunohistochemical
features of MF or FMF in 6/11 (55%) and 4/11 (36%) target lesions, respectively (Figs. 1 and 2). Monoclonal TCR
rearrangement of the target lesions before treatment was positive in 7/7 (100%) cases and in 3/7 (43%) at 2 months
post-treatment.
Fig. (1). a. Target lesion of a folliculotropic pCTNKCL on the buttocks. 1b. Complete clinical cure after 2 months. 1c. Histology
illustrating  folliculotropic  pCTNKCL  before  treatment  (H/E  histochemical  stain,  40x).  1d.  Histological  clearing  of  atypical
lymphocytes  two  months  after  IM  treatment  (H/E  histochemical  stain,  10x).
3.2. CAILS Scores
The study results are listed in Tables 2 and 3. The mean overall CAILS score (T0-T2) was reduced by 58.2%. The
erythema, scaling and plaque elevation mean scores (T0-T2) were improved by 73.6%, 93.9% and 97.7% respectively,
all  statistically  significant  (p<0.0001).  No  hyper  or  hypopigmentation  was  observed  at  baseline.  Mild  to  moderate
hyperpigmentation appeared in 8/11 (73%) of the target lesions. No reduction in lesion size was observed in any of the
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target and control lesions (Figs. 1-4).
Fig. (2). a. Hyperpigmented postinflammatory target MF lesion (yellow arrow) and erythemato-squamous control MF lesion (red
arrow) 2 months after treatment. 2b. Histology illustrating patch/plaque stage MF before and 2c. Histological clearing 2 months after
treatment (H/E histochemical stain, x10).
Fig. (3). a. Patch/plaque stage MF of the knee, 3b, 2 months after treatment. Note slight persistent hyperpigmentation.
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Fig. (4). a. Patch/plaque stage MF of the knee, 4b. 2 months after treatment. Note slight persistent hyperpigmentation.
Table 2. Mean absolute differences between T0 and T2 and significance of the difference.
Variable N Mean SD SE Min Q1 Median Q3 Max Student p-value
ErythdT0T2 11 3.818 1.401 0.42 2.0 3.0 4.00 5.0 6.0 <.0001
ScalingdT0T2 11 3.273 1.421 0.43 1.0 2.0 4.00 4.0 6.0 <.0001
PlaquedT0T2 11 3.909 1.221 0.37 2.0 3.0 4.00 4.0 6.0 <.0001
HyppigmdT0T2 11 -1.636 1.433 0.43 -4.0 -2.0 -2.00 0.0 0.0 0.0036
SizedT0T2 11 0.000 0.000 0.00 0.0 0.0 0.00 0.0 0.0
TotaldT0T2 11 9.364 2.580 0.78 6.0 7.0 9.00 12.0 14.0 <.0001
 
Table 3. Comparison of the relative differences (%) between Target and Control (PT0T2 et PC0C2).
Variable N Mean SD SE Min Q1 Median Q3 Max
Student
p-value
dErythpT0T2C 11 73.636 18.148 5.47 50.0 50.0 75.00 83.3 100.0 <.0001
dScalingpT0T 11 93.939 10.601 3.20 75.0 83.3 100.00 100.0 100.0 <.0001
dPlaquepT0T2 11 97.727 7.538 2.27 75.0 100.0 100.00 100.0 100.0 <.0001
dHyppigmpT0T 0 . . . . . . . .
dSizepT0T2C0 11 3.030 10.050 3.03 0.0 0.0 0.00 0.0 33.3 0.34
dTotalpT0T2C 11 58.235 12.910 3.89 37.5 46.2 60.00 68.3 75.0 <.0001
3.3. Recurrence
After a follow-up of 6 months after treatment, 2 out of 11 target lesions (18%) presented de novo erythema, slight
infiltration and scaling, suggestive of MF recurrence. The hyperpigmentation observed at the evaluation at 2 months
was significantly attenuated in 10 out of 11 cases at 6 months.
No beneficial or detrimental effects were noted for the surrounding control lesions.
3.4. Adverse Effects
Five days after the first and second application of IM, all the patients experienced treatment-related adverse effects.
The scores for burning sensations, oozing and crusting were 1.6, 0.7, 1, and 1.2, 0.3, 0.5, respectively. All the patients
accepted well the IM-inherent adverse effects and were never a reason to interrupt the trial.
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4. DISCUSSION
Although the precise action mechanisms of IM on neoplastic lymphocytes should be further investigated, the IM-
induced pro-inflammatory and pro-apoptotic storm [12] through activation of the PKC isoform PKCδ is likely to be
involved in the anti-neoplastic action on MF lymphocytes [14].
As the control lesions in the direct vicinity of the target lesions were unaltered one may suggest that IM only acts
locally at the site of application and does not generate a more expanded immune effect. This is in contrast to topical
agents such as resiquimod, inducing not only a loco-regional immune effect, but also a systemic immune stimulation by
enhancing  circulating  dendritic  cells  [20].  On  the  other  hand,  other  authors  described  an  adjuvant  effect  of  IM by
showing that its action on subcutaneous tumors simultaneously generated anti-cancer CD8+ T-cells, able to regress
metastases and distant metastases by upregulating CD80 and CD86 expression on dendritic cells and by stimulating
CD8+ T-cell induction when co-delivered with a protein antigen [21].
This  pilot  study  supports  the  hypothesis  that  the  action  spectrum  of  IM  is  not  only  limited  to  neoplastic
keratinocytes  and  melanocytes,  but  also  expands  to  neoplastic  lymphocytes  of  MF.
Due to the relative difficulty of finding 3 highly similar test MF lesions (IM target lesion gel, placebo gel lesion and
no treatment lesion) in one patient, we decided in this pilot setting not to include a placebo gel group. Previous studies
with  IM  on  AK  demonstrated  that  IM  was  significantly  superior  to  placebo  gel  in  terms  of  partial  and  complete
clearance and the median percentage reduction in baseline AK lesions for patients treated with IM gel ranged from 75%
to 100% compared with 0% for vehicle gel (P < .0001 vs vehicle) [2]. Furthermore, the 13.3% placebo effect in the AK
studies could also be attributed to the natural evolution of “coming and going” of AK’s. In addition, the vehicle gel
could have had a keratolytic effect on the hyperkeratotic part of the AK’s, explaining a placebo effect, a phenomenon
that does not exist in MF lesions.
Even if only 11 target lesions of 10 T2b MF patients were included in this pilot study, the results remain interesting,
in  particular  in  comparison  to  other  available  topical  treatments.  In  fact,  for  T2  MF,  the  topical  retinoids  group,
including bexarotene 1% gel, tazarotene 0,1% gel and alitretinoine 0,1% gel, presented a complete cure of 21%, 33%
and 100% (one single patient), respectively [22 - 24]. The potent to very strong corticosteroids achieved a complete
response in 25% in T2 MF patients [25, 26]. The topical immunomodulators such as imiquimod 5% cream presented a
50% cure rate [27] and resiquimod 0.03% and 0.06% gel presented a 30% cure rate in 12 IA-IIA MF patients [20].
Topical  chemotherapies  using  mechlorethamine  or  carmustine  in  T2  MF  patients  achieved  about  a  50%  complete
response [28 - 31].
IM  already  achieved  a  good  clinical  response  after  2  months  versus  10-19  months  with  mechlorethamine  or
carmustine [28 - 32] or versus 20.1 months for bexaroten gel [22]. Hence, IM gel seems to act more rapidly compared
to other topical agents.
That TCR monoclonality was still present in 3 of 7 target lesions at T2 is probably related to the high sensitivity of
the PCR technique, whereas the histological and immunohistological analysis do not favor anymore a diagnosis of MF.
Despite this fact, there was only an 18% recurrence rate after 6 months. This may suggest that the histological and
immunohistological assessment of treatment results are better predictors of a persisting favorable treatment response
than TCR rearrangement analysis.
The  number  of  cases  is  too  small  to  determine  whether  the  intensity  of  adverse  reactions  and/or  the  post
inflammatory  hyperpigmentation  after  application  are  predictive  of  a  favorable  treatment  outcome  or  not.
The adverse effects of IM were identical to those experienced using IM gel as AK therapy [1, 2]. In general, the
adverse effects were less severe following the second IM application, probably linked to an already partial remission of
the target lesion after the first IM application. Hyperpigmentation of the target lesion was frequent (8 out of 11 target
lesions) but faded over time.
Final dosing regimens and the place of IM among the armamentarium of topical treatments against MF should be
evaluated on larger series. Whether other ingenol derivatives are also effective as anti-MF topical agent remains to be
determined [33]. One major drawback of IM is that it is only approved for a body surface limited to 25 cm2. Currently
ingenol disoxate is being developed for use on larger surfaces, up to 250 cm2, as has been recently published for field
AK [34].
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CONCLUSION
In conclusion, this pilot study suggests that IM gel merits further evaluation as a topical alternative treatment for
patients with localized patch/plaque stage MF skin lesions not exceeding 25 cm2, in a placebo-controlled study design.
This study provides an initial proof of concept that IM also acts against neoplastic MF lymphocytes.
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